Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Latiglutenase
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : First Wave BioPharma
Deal Size : Undisclosed
Deal Type : Merger
First Wave BioPharma Completes Business Combination with ImmunogenX, Adding Latiglutenase
Details : Through acquisition, First Wave advances its lead product IMGX003 (latiglutenase) for treating celiac disease, currently under Phase II clinical trials.
Product Name : IMGX003
Product Type : Enzyme
Upfront Cash : Undisclosed
March 14, 2024
Lead Product(s) : Latiglutenase
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : First Wave BioPharma
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Latiglutenase
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : First Wave BioPharma
Deal Size : Undisclosed
Deal Type : Merger
Details : Through the acquisition, First Wave will advance its lead product candidate IMGX003 (latiglutenase) for research & development and commercialization purposes. Currently, it is being evaluated in Phase II clinical trial studies for the treatment of Celiac...
Product Name : IMGX003
Product Type : Enzyme
Upfront Cash : Undisclosed
December 18, 2023
Lead Product(s) : Latiglutenase
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : First Wave BioPharma
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Latiglutenase
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Mayo Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable
ImmunogenX and Mayo Clinic Celiac Disease Study Published in Gastroenterology
Details : The company is developing latiglutenase (IMGX003) for celiac disease therapy. ImmunogenX is also developing a diagnostic tool for celiac disease management as a minimally-invasive monitor of villus health to follow the state of recovery of a celiac patie...
Product Name : IMGX003
Product Type : Enzyme
Upfront Cash : Inapplicable
December 08, 2022
Lead Product(s) : Latiglutenase
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Mayo Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Latiglutenase
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable
ImmunogenX and Mayo Clinic Successfully Complete the CeliacShield Trial
Details : CeliacShield Trial is a double-blind, placebo controlled, gluten challenge trial of the efficacy, safety and tolerability of 6-weeks treatment of Latiglutenase (IMGX003) administration in patients with well-controlled celiac disease.
Product Name : IMGX003
Product Type : Enzyme
Upfront Cash : Inapplicable
March 18, 2021
Lead Product(s) : Latiglutenase
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Latiglutenase
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Enrollment Begins for Latiglutenase (IMGX003) Phase 2b Trial for Treatment of Celiac Disease
Details : The trial will test the safety and efficacy of the company’s lead therapeutic candidate, Latiglutenase (IMGX003).
Product Name : IMGX003
Product Type : Enzyme
Upfront Cash : Inapplicable
February 13, 2020
Lead Product(s) : Latiglutenase
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable